MANTIS Startup to Disrupt Online Advertising Industry With Advanced Online Video Vetting AI Technology
Mantis-ai.com will launch its Artificial Intelligence (AI) tool for the first time, which will be available for advertisers during the #vivatech conference in Paris, May 2018 at startup booth: D17-001, Viva Technology Paris 24-26 May, 2018.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180522005610/en/
Mantis working process (Graphic: AETOSWire)
Over the past year, SMOs released several official reports surrounding decisions by the largest global advertisers to withdraw ad campaigns from the top four online video publishers, due to failures in online video content vetting and lack of advertiser control over ad placement within relevant content.
Mantis is a video moderation system that uses state-of-the-art AI techniques to identify video content that is relevant for advertisers through a highly efficient content vetting system. The Mantis vetting system detects, classifies and categorizes relevant content based on specified brand attributes and characteristics, ensuring brand safety and efficient spending of online advertising budgets.
Feras Maddah the CEO says, “Advertisers will now have the option of applying pressure on publishers to only place ads in videos that adhere to a brand’s specified ‘safe list.’ This new tool will allow advertisers to conduct online video campaigns more effectively and efficiently, securing brand perception associated with selected content. Within the next 3 months, ongoing trials will conclude and results of the trials will be published with full reports on Mantis’ performance.”
Dr. (PhD) Bernard Ghanem, the Project Director for Mantis says, “Mantis presents an innovative tool for the online advertising world. The system uses sophisticated AI techniques developed in-house to translate brand-safe attributes (similar to those found in an advertising campaign brief) into visual cues that can be very quickly found and recognized in a video. Mantis technology can be used by advertisers in two main ways: (1) to quickly earmark thousands of videos that follow brand specific attributes for ad placement or (2) to assess whether videos with ads already placed in them are coherent with these brand attributes.
Maddah adds, “Mantis will significantly help reduce wastage in advertising spending caused by ad spillovers onto irrelevant or brand-unsafe content and, in turn, improve budget allocation”.
Dr. Ghanem outlines two major benefits of Mantis, “First, Mantis can determine if an activity or cue in a video can be considered brand-safe or unsafe, and consequently, alert the advertiser to whether or not an ad should be placed in that specific video.
Second, Mantis is equipped with an added-value feature where ads can be placed at specific time intervals in a video based on its relevance and favorability to the brand. For example, Mantis can enable advertisers to embed banner ads for sportswear at the exact time a basketball dunk happens in a video across the publisher’s platform. Mantis does this by automatically detecting when that specific activity (basketball dunk) occurs in the video and earmarks it for ad placement.”
For more information, please visit:
http://mantis-ai.com/
http://www.mantis-ai.com/news
Twitter:
@mantis_ai
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180522005610/en/
Contact information
Mantis
FERAS ALMADDAH, +966560690606
Chief
Executive Officer
f.almaddah@mantis-ai.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Daiichi Sankyo Announces the Initiation of the Development of Oral Triple Combination Lipid-Lowering Tablets to Support the Management of LDL-C30.8.2025 19:00:00 EEST | Press release
Daiichi Sankyo Europe is pleased to announce the initiation of the development of new oral triple combination tablets in Europe of bempedoic acid, ezetimibe, and different doses of a statin (atorvastatin or rosuvastatin), with the potential to lower low-density lipoprotein cholesterol (LDL-C) levels.9 It is well known that combination therapies reduce the pill burden for patients, potentially enhancing treatment adherence and facilitating treatment with a goal of improving cardiovascular outcomes.9,10 “As bempedoic acid and ezetimibe are already approved as a single-dose therapy, the development of an oral triple combination tablet with different doses of a statin, can make it easier for physicians to tailor treatment to the individual needs of each patient,” says Dr. Stefan Seyfried, Vice President and Head Medical Affairs Specialty Medicines, Daiichi Sankyo Europe. “This approach exemplifies our dedication to our motto: ‘we care for every heartbeat’.” “The management of dyslipidaemia
Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial30.8.2025 17:30:00 EEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced plans to initiate a Phase 3 cardiovascular outcomes trial (CVOT) to evaluate the potential of zilebesiran to reduce the risk of major adverse cardiovascular events. This decision is informed by results from the comprehensive KARDIA Phase 2 program, including KARDIA-3 results presented today as a late-breaking abstract at the European Society of Cardiology (ESC) Congress in Madrid, Spain. Zilebesiran is an investigational subcutaneously administered RNAi therapeutic which, in the KARDIA Phase 2 program, has shown reductions in blood pressure by targeting liver-expressed angiotensinogen (AGT), the most upstream precursor in the Renin-Angiotensin-Aldosterone System (RAAS), which plays a key role in blood pressure regulation and impacts cardiovascular and renal health. KARDIA-3, the third Phase 2 study in the KARDIA program, evaluated the efficacy and safety of zilebesiran in patients with
BeOne Medicines Announces Positive Topline Results for Sonrotoclax in Relapsed or Refractory Mantle Cell Lymphoma (MCL)29.8.2025 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from a Phase 1/2 study (BGB-11417-201) of sonrotoclax, a next-generation and potentially best-in-class investigational BCL2 inhibitor, in adult patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL), following treatment with a Bruton’s tyrosine kinase inhibitor (BTKi) and anti-CD20 therapy. BeOne plans to present the full data at an upcoming medical meeting. “For people with relapsed or refractory mantle cell lymphoma, the disease is aggressive, the treatment landscape fragmented, and the outcomes unacceptably poor. These topline results for sonrotoclax underscore its potential to deliver meaningful and durable responses and offer the first BCL2 inhibitor for patients with R/R MCL, if approved,” said Lai Wang, PhD, Global Head of R&D, BeOne Medicines. “These data add to the remarkable progress we’ve seen over the past five years in treating B-cel
Oulu2026 – European Capital of Culture: Oulu to Unveil Full European Capital of Culture 2026 Programme – Live Stream on 4 September 202529.8.2025 11:46:00 EEST | Press release
Hundreds of partners are creating a year in which Northern Finland becomes a new hub of culture. The programme will offer something for everyone: large-scale exhibitions, festivals across all genres, world premieres, performing arts, village celebrations, permanent artworks, sports, and community events across a vast region of 40 municipalities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250829591577/en/ Oulu, with its 39 partner municipalities in Northern Finland, will step into the spotlight as European Capital of Culture 2026. The full programme will be officially launched on Thursday 4 September 2025 in Oulu, streamed live across Europe. The Oulu2026 programme is built around the theme of Cultural Climate Change, meaning a lasting enrichment of cultural life – connecting people through world-class experiences, creativity, and new ways of thinking. “2026 will be a transformative year – for our city, for Northern Finla
Nippon Sanso Holdings Group Unifies Global Brand Logo Launching the "NIPPON SANSO" Brand Worldwide29.8.2025 09:00:00 EEST | Press release
Nippon Sanso Holdings Corporation (President CEO: Toshihiko Hamada) will unify the brand logo for its industrial gas business globally and implement the change in stages. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250828253560/en/ Until now, our group has operated industrial gas businesses worldwide using the same symbol mark, while adapting to each region. To further enhance recognition and understanding of our group as a unified entity among a broad range of stakeholders, and to maximize corporate value and achieve sustainable growth, we have decided to unify the brand for our industrial gas businesses as "NIPPON SANSO" and standardize the brand logo globally. Moving forward, we will continue striving to be a trusted company for all stakeholders as a globally recognized brand. *Please note that Thermos Group, which operates the consumer household goods business within our group, will not change its brand logo. *The log
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom